SGLT-2 Inhibitors Use in Hospitalized Patients in France: A Cross-Sectional Study

IF 2.5 4区医学 Q3 PHARMACOLOGY & PHARMACY

Fundamental & Clinical Pharmacology Pub Date : 2026-02-22 DOI:10.1111/fcp.70076

Maxime Demourgues, Julien Bezin, Romain Griffier, Antoine Pariente, Pernelle Noize, Sibylle de Germay

{"title":"SGLT-2 Inhibitors Use in Hospitalized Patients in France: A Cross-Sectional Study","authors":"Maxime Demourgues, Julien Bezin, Romain Griffier, Antoine Pariente, Pernelle Noize, Sibylle de Germay","doi":"10.1111/fcp.70076","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Sodium glucose co-transporter type 2 inhibitors (SGLT2i) were initially developed as glucose-lowering drugs for diabetic patients. A few years after their market authorization in Europe, their indications were expanded to include first, heart failure (HF) and, subsequently, chronic kidney disease (CKD). These expansions led to a rapid increase in the use of this drug class and a diversification of the treated patient profile in the “real-life.”</p>\n </section>\n \n <section>\n \n <h3> Objectives</h3>\n \n <p>Describe in-hospital SGLT2i user profiles and evaluate compliance with guidelines.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A descriptive cross-sectional study was conducted using the Bordeaux University Hospital's clinical data warehouse. It included a random sample of 250 hospital stays of different patients with at least one administration of SGLT2i between February 1, 2022, and January 31, 2023. SGLT2i user profiles were described in terms of indications. Drug co-prescriptions were also described to evaluate compliance with guidelines.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The majority of patients were aged 60–79 (59.6%), and were men (75.2%). HF was found in 87.2% of the patients treated with SGLT2i, followed by T2DM (45.2%) and CKD (21.2%). The most frequent indication profiles were HF without type II diabetes or CKD (42.0%) followed by HF and diabetes without CKD (26.0%). No patient had CKD as the sole indication. Prescriptions were considered compliant with guidelines for 76.4% of patients. Suboptimal prescriptions were mainly due to absence of another recommended drug without justification.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>SGLT2i are now primarily used to treat HF. Their therapeutic potential in CKD appears to be still underestimated. Overall, compliance with guidelines appears satisfactory.</p>\n </section>\n </div>","PeriodicalId":12657,"journal":{"name":"Fundamental & Clinical Pharmacology","volume":"40 2","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2026-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Fundamental & Clinical Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/fcp.70076","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Sodium glucose co-transporter type 2 inhibitors (SGLT2i) were initially developed as glucose-lowering drugs for diabetic patients. A few years after their market authorization in Europe, their indications were expanded to include first, heart failure (HF) and, subsequently, chronic kidney disease (CKD). These expansions led to a rapid increase in the use of this drug class and a diversification of the treated patient profile in the “real-life.”

Objectives

Describe in-hospital SGLT2i user profiles and evaluate compliance with guidelines.

Methods

A descriptive cross-sectional study was conducted using the Bordeaux University Hospital's clinical data warehouse. It included a random sample of 250 hospital stays of different patients with at least one administration of SGLT2i between February 1, 2022, and January 31, 2023. SGLT2i user profiles were described in terms of indications. Drug co-prescriptions were also described to evaluate compliance with guidelines.

Results

The majority of patients were aged 60–79 (59.6%), and were men (75.2%). HF was found in 87.2% of the patients treated with SGLT2i, followed by T2DM (45.2%) and CKD (21.2%). The most frequent indication profiles were HF without type II diabetes or CKD (42.0%) followed by HF and diabetes without CKD (26.0%). No patient had CKD as the sole indication. Prescriptions were considered compliant with guidelines for 76.4% of patients. Suboptimal prescriptions were mainly due to absence of another recommended drug without justification.

Conclusion

SGLT2i are now primarily used to treat HF. Their therapeutic potential in CKD appears to be still underestimated. Overall, compliance with guidelines appears satisfactory.

查看原文本刊更多论文

SGLT-2抑制剂在法国住院患者中的应用：一项横断面研究

背景：葡萄糖共转运蛋白2型抑制剂钠最初是作为糖尿病患者的降糖药物而开发的。在欧洲上市几年后，它们的适应症扩大到包括心力衰竭（HF）和随后的慢性肾脏疾病（CKD）。这些扩展导致这类药物的使用迅速增加，并在“现实生活”中治疗患者的多样化。“目的：描述医院内SGLT2i用户资料并评估指南的遵守情况。方法：采用波尔多大学医院临床数据仓库进行描述性横断面研究。该研究包括在2022年2月1日至2023年1月31日期间至少接受过一次SGLT2i治疗的250名住院患者的随机样本。根据适应症描述了SGLT2i用户概况。还描述了药物联合处方，以评估指南的遵守情况。结果：60 ~ 79岁患者居多（59.6%），男性占75.2%。在接受SGLT2i治疗的患者中，HF发生率为87.2%，其次是T2DM（45.2%）和CKD（21.2%）。最常见的适应症是无II型糖尿病或CKD的心衰（42.0%），其次是无CKD的心衰和糖尿病（26.0%）。没有患者将CKD作为唯一适应症。76.4%的患者认为处方符合指南。次优处方主要是由于没有其他推荐药物而没有理由。结论：SGLT2i目前主要用于治疗心衰。它们在慢性肾病中的治疗潜力似乎仍被低估。总的来说，对指导方针的遵守似乎令人满意。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Fundamental & Clinical Pharmacology 医学-药学

CiteScore

5.30

自引率

6.90%

发文量

111

审稿时长

6-12 weeks

期刊介绍： Fundamental & Clinical Pharmacology publishes reports describing important and novel developments in fundamental as well as clinical research relevant to drug therapy. Original articles, short communications and reviews are published on all aspects of experimental and clinical pharmacology including: Antimicrobial, Antiviral Agents Autonomic Pharmacology Cardiovascular Pharmacology Cellular Pharmacology Clinical Trials Endocrinopharmacology Gene Therapy Inflammation, Immunopharmacology Lipids, Atherosclerosis Liver and G-I Tract Pharmacology Metabolism, Pharmacokinetics Neuropharmacology Neuropsychopharmacology Oncopharmacology Pediatric Pharmacology Development Pharmacoeconomics Pharmacoepidemiology Pharmacogenetics, Pharmacogenomics Pharmacovigilance Pulmonary Pharmacology Receptors, Signal Transduction Renal Pharmacology Thrombosis and Hemostasis Toxicopharmacology Clinical research, including clinical studies and clinical trials, may cover disciplines such as pharmacokinetics, pharmacodynamics, pharmacovigilance, pharmacoepidemiology, pharmacogenomics and pharmacoeconomics. Basic research articles from fields such as physiology and molecular biology which contribute to an understanding of drug therapy are also welcomed.